Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. Covid-19 : sur Facebook, nouvelle série d'infox sur la pandémie by Africa Check published on 2020-06-15T10:40:48Z Users who like Covid-19 : sur Facebook, nouvelle série d'infox sur la pandémie Participants ≥16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study. Les chercheurs ont comparé les symptômes des enfants positifs au Covid-19, à ceux d'enfants négatifs à la maladie. Male or female participants between the ages of 18 and 55 years, inclusive, 65 and 85 years, inclusive, or ≥12 years, inclusive, at randomization (dependent upon study phase). https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. Positions determined on head-to-head points per game: Bra 2.000, Ghivizzano 1.333, Fezzanese 0.500. Please remove one or more studies before adding more. None of the teams that were relegated in a normal fashion, by virtue of their finishing positions and unsuccessful playouts in the 2018–19 Serie C season will take part in this campaign. The season was ended in advance by the Italian Football Federation on 20 May 2020, after a two-month suspension, due to the COVID-19 pandemic in Italy. To obtain contact information for a study center near you, click here. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Why Should I Register and Submit Results? Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. It represents the fourth tier in the Italian football league system. Teams returning to Serie D from higher divisions last season as a result of bankruptcy and/or administrative issues include Foggia, Palermo, Lucchese and Arzachena. ClinicalTrials.gov Identifier: NCT04368728, Interventional Previous vaccination with any coronavirus vaccine. Brian Beutler. 6 points deducted due to financial irregularities. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. [5], On 31 July 2019, the Lega Nazionale Dilettanti announced to have admitted Agropoli, Legnago Salus, Pomezia, Olympia Agnonese, Legnano, Gladiator, Tamai and Anagni to fill in all the league vacancies. North Korea. Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19, History of chronic smoking within the prior year, Anticipating the need for immunosuppressive treatment within the next 6 months. Receipt of medications intended to prevent COVID 19. As elicited by investigational site staff. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Il y en avait respectivement 1987 et 476. Washington County reported 114 new cases of the coronavirus on Thursday and 124 Friday, for a two-day total of 238, according to the Pennsylvania Department of Health. Subscribe to our nightly newsletter . Epub 2020 Aug 12. The composition of the league will involve nine divisions, grouped geographically and named alphabetically. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. Scopri su Sky Sport la classifica completa di Serie A 2020/2021 aggiornata in tempo reale The Immense Stakes of the Biden COVID Response. U.S. Department of Health and Human Services. North Texas Infectious Diseases Consultants, P.A. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Individual Participant Data (IPD) Sharing Statement: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. 1 point deducted due to financial irregularities. This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. Serie C did not resume play on this date. Note that participants <18 years of age cannot be enrolled in the EU. More than 30 leading STM publishers have committed to making all of their COVID-19 and coronavirus-related publications immediately accessible. More than 4.2 million Americans have their first COVID-19 vaccine. In support of global efforts to address the COVID-19 pandemic, the American Physical Society (APS) has committed to making potentially relevant, peer-reviewed articles from our Physical Review journals more discoverable, accessible, and usable.. We have identified a collection of articles potentially relevant to researchers, health professionals, and others working on the COVID-19 … Selena Gomez Slams Facebook for Coronavirus Misinformation The "Rare" singer calls out the company for allegedly allowing false claims about COVID … Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study. N Engl J Med. [Epub ahead of print]. NBCUniversal 'The More You Know' COVID-19 Campaign: In partnership with the White House, CDC, and Health and Human Services, NBCUniversal created a series of videos and graphics, available in both English and Spanish, to help educate people around the country about how they can reduce their risk and prevent the spread of COVID-19. Afghanistan. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04368728. 2020 Dec 10. doi: 10.1056/NEJMoa2034577. Nature. ... D360’s Bad Ideas in National Security series features short articles from CSIS and outside scholars on recently considered and not too obvious bad ideas in the defense and foreign policy space. Il Dipartimento Interregionale comunica a … Phase 1 only: Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). Links with this icon indicate that you are leaving the CDC website.. Phase 1 only: Regular receipt of inhaled/nebulized corticosteroids. Montebelluna finished ahead of Vigasio on head-to-head points: Vigasio 1–3 Montebelluna. Phases 1 and 2 only: Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV). "Stop ai Dilettanti: adesso Palermo, Mantova e le altre aspettano la C", "Ammissioni e ripescaggi ai campionati nazionali della LND", "ECCELLENZA, ECCO LE SQUADRE PROMOSSE IN SERIE D: I VERDETTI", "SPAREGGI ECCELLENZA: ECCO LE SETTE SQUADRE PROMOSSE IN SERIE D", "Stagione Sportiva 2019/2020 Comunicato Ufficiale N° 5 del 18/7/2019", "A Rezzato si chiude un'era Addio serie D: cosa accadrà? Brian Beutler. December 02, 2020. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. The paper reports, “If coronavirus restrictions allow, the Royal Family will certainly gather for a private celebration, and the Duke and Duchess of … Positions determined on head-to-head points: Nocerina 8, Grumentum 5, Nardò 2. Your home for CNN's podcasts, showcasts and livestreams. Serie D - Claudio Davitti allenatore Scandicci sull'Emergenza CoronaVirus 16 marzo 2020 The 2019–20 Serie C was the sixth season of the unified Serie C division, the third tier of the Italian football league system.The season was scheduled to run from 24 August 2019 to 26 April 2020, however, on 9 March 2020, the Italian government halted the league until 3 April 2020 due to the COVID-19 pandemic in Italy. Podcast Episode. Republican Silence Is a Bet Against Democracy. Phase 1 only: SARS-CoV-2 NAAT-positive nasal swab within 24 hours before receipt of study intervention. COVID-19. Microsite. Choosing to participate in a study is an important personal decision. At Brill we have opened up books and articles on topics such as public health, distance learning, crisis research. Phase 1 only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality. 2020 Oct 14. doi: 10.1056/NEJMoa2027906. I club di Serie D, prossimi alla ripresa del campionato dopo un lungo stop, potranno contare su una convenzione stipulata tra LND e FederLab (Associazione Nazionale Strutture Ambulatoriali) per accedere ai test Covid per i propri tesserati a un prezzo agevolato.. Di seguito tutti i dettagli nella nota ufficiale della Lega Nazionale Dilettanti:. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. It represents the fourth tier in the Italian football league system. Phase 1 only: Positive serological test for SARS-CoV-2 IgM and/or IgG antibodies at the screening visit. Valparaiso postpones second MVC series against Illinois State due to COVID-19 The Valpo men's team postponed a nonconference game against Mount St. Joseph, originally scheduled for … Even though researchers around the country quickly began creating tests that could diagnose Covid-19, many said they were hindered by the F.D… Due to a continuing combination of positive COVID-19 tests, contact tracing and subsequent quarantining of individuals within the Omaha hockey program, the Omaha at North Dakota series scheduled for this weekend, Friday, Jan. 8 and Saturday, Jan. 9, at Ralph Engelstad Arena in Grand Forks, N.D. has been postponed. Findings In this case series that included 5700 patients hospitalized with COVID-19 in the New York City area, the most common comorbidities were hypertension, obesity, and diabetes. Get the latest research information from NIH: You have reached the maximum number of saved studies (100). The season was ended in advance by the Italian Football Federation on 20 May 2020, after a two-month suspension, due to the COVID-19 pandemic in Italy. COVID-19 Support Group: Confronting the Emotional Challenges of Illness Jul 21, 2020 We reached out to our members to ask how they navigate the fear, uncertainty, sadness, numbness, anger, and despair that are common features of the long-haul experience. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. Participants who, in the judgment of the investigator, are at risk for acquiring COVID-19. Brian Beutler. COVID-19 is an emerging, rapidly evolving situation. Gianluigi Donnarumma, AC Milan’s starting goalkeeper, has recently added his name to the list of Serie A players with Covid-19 and was therefore absent in … Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain as self-reported on electronic diaries. The 2019–20 Serie D was the seventy-second edition of the top level Italian non-professional football championship. Phase 1 only: Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel). Headlines, analysis and interviews created for your ears. Neera Tanden or Bust. J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States, 84109, J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States, 84121, Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID), Annandale, Virginia, United States, 22003, Midlothian, Virginia, United States, 23114, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States, 98101, Wenatchee, Washington, United States, 98801, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Hospital Santo Antonio/ Associacao Obras Sociais Irma Dulce, CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda (Casa Branca), CRS Clinical Research Services Berlin GmbH, CRS Clinical Research Services Mannheim GmbH, Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher, Johannesburg, Gauteng, South Africa, 2113, Tiervlei Trial Centre, Basement Level, Karl Bremer Hospital, Cape Town, Western CAPE, South Africa, 7530, Ankara Universitesi Tip Fakultesi, Ibni Sina Hastanesi, Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul Universitesi-Cerrahpasa, Cerrahpasa Tip Fakultesi, Sakarya Universitesi Egitim ve Arastirma Hastanesi. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. Differences, similarities between first two coronavirus vaccinations authorized in U.S. 5 Ways the Pandemic Will Be Different in 2021 Look for innovations in COVID … Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. N Engl J Med.  (Clinical Trial), Triple (Participant, Care Provider, Investigator), A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS, Experimental: Low dose, 18-55 years of age (2 doses), Experimental: Low-mid dose, 18-55 years of age (2 doses), Experimental: Mid dose, 18-55 years of age (2 doses), Experimental: Low dose, 65-85 years of age (2 doses), Experimental: Low-mid dose, 65-85 years of age (2 doses), Experimental: Mid dose, 65-85 years of age (2 doses), Experimental: Mid dose, ≥12 years of age (2 doses), Placebo Comparator: Placebo, 18-55 years of age, Placebo Comparator: Placebo, 65-85 years of age, Placebo Comparator: Placebo, ≥12 years of age, Experimental: High dose, 18-55 years of age (2 doses), Vaccination of Placebo recipients with BNT162b2 - Stage 1, Vaccination of placebo recipients with BNT162b2 - Stage 2, 12 Years and older   (Child, Adult, Older Adult), Birmingham, Alabama, United States, 35216, Huntsville, Alabama, United States, 35801, Huntsville, Alabama, United States, 35802, Alliance for Multispecialty Research, LLC, Chinle Comprehensive Health Care Facility, Johns Hopkins Center for American Indian Health, Whiteriver, Arizona, United States, 85941, Anaheim, California, United States, 92801, Long Beach, California, United States, 90806, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States, 90027, Los Angeles, California, United States, 90057, North Hollywood, California, United States, 91606, Redding, California, United States, 96001, Sacramento, California, United States, 95815, Sacramento, California, United States, 95817, San Diego, California, United States, 92123-1881, Santa Clara, California, United States, 95051, Valley Village, California, United States, 91607, Walnut Creek, California, United States, 94598, Milford, Connecticut, United States, 06460, Yale Center for Clinical Investigations (CSRU), New Haven, Connecticut, United States, 06519, Coral Gables, Florida, United States, 33134, Fleming Island Center for Clinical Research, Fleming Island, Florida, United States, 32003, Jacksonville Center for Clinical Research, Jacksonville, Florida, United States, 32216, Jacksonville, Florida, United States, 32256, Stockbridge, Georgia, United States, 30281, Bardstown, Kentucky, United States, 40004, Metairie, Louisiana, United States, 70006, New Orleans, Louisiana, United States, 70121, Shreveport, Louisiana, United States, 71101, Shreveport, Louisiana, United States, 71103, Baltimore, Maryland, United States, 21201, University of Maryland, Center for Vaccine Development and Global Health, Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States, 21224, Boston, Massachusetts, United States, 02118, UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States, 01655, Farmington Hills, Michigan, United States, 48334, Gulfport, Mississippi, United States, 39503, Chesterfield, Missouri, United States, 63005, Saint Louis, Missouri, United States, 63141, Bozeman Health Deaconess Hospital dba Bozeman Health Clinical Research, Methodist Physicians Clinic / CCT Research, Wake Research-Clinical Research Center of Nevada, LLC, Raritan, New Jersey, United States, 08869, Somers Point, New Jersey, United States, 08244, Shiprock, New Mexico, United States, 87420, Binghamton, New York, United States, 13901, Rochester, New York, United States, 14609, Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States, 14621, PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States, 27518, Charlotte, North Carolina, United States, 28209, Duke University Medicine Circle- Duke Early Phase Clinical Research Unit, Durham, North Carolina, United States, 27710, Greensboro, North Carolina, United States, 27408, Hickory, North Carolina, United States, 28601, Raleigh, North Carolina, United States, 27609, Raleigh, North Carolina, United States, 27612, Salisbury, North Carolina, United States, 28144, Wilmington, North Carolina, United States, 28401, Winston-Salem, North Carolina, United States, 27103, Fargo, North Dakota, United States, 58104, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229-3039, University Hospitals Cleveland Medical Center, Kaiser Permanente Northwest-Center for Health Research, Lehigh Valley Health Network/Network Office of Research and Innovation, Allentown, Pennsylvania, United States, 18102, Warwick, Rhode Island, United States, 02886, Little River, South Carolina, United States, 29566, Loris, South Carolina, United States, 29569, Dakota Dunes, South Dakota, United States, 57049, Kingsport, Tennessee, United States, 37660, Knoxville, Tennessee, United States, 37920, Nashville, Tennessee, United States, 37203, Tullahoma, Tennessee, United States, 37388. Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19; Phase 1 only: Individuals at high risk for severe COVID-19, including those with any of the following risk factors: Hypertension Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment, technology, video and pictures. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Twenty-eight clubs were promoted from the Eccellenza as league winners, plus one as the Coppa Italia Dilettanti winners and seven more as national playoff winners. ‘Brooklyn Nine-Nine’, ‘Good Girls’ & ‘Never Have I Ever’ Among Universal TV Series Delaying Production Return Amid Covid-19 Surge In Los Angeles Nellie Andreeva 2 days ago. Protocollo Covid in Serie D: accordo Lnd – Federlab - YouTube Following the 2018–19 season which saw the participation of former Serie A teams such as Bari, Modena, Cesena, Avellino and Reggio Audace (all promoted to Serie C after their first season), new legal incarnations of former top flight clubs Palermo (excluded from Serie B due to financial issues) and Foggia took part in the league, under the Article 52 of N.O.I.F. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. [3][4], A number of vacancies are also expected to be created by some clubs failing to register in Serie C and Serie D. The Serie D committee will fill in these vacancies with additional teams to be chosen among the ones relegated from the league in 2018–19, and other ones who played and lost the Eccellenza promotion playoffs; a classification of the clubs who applied for these vacancies was announced on 18 July 2019. Due to what the league called a combination of positive COVID-19 tests, contact tracing and subsequent quarantining of individuals within the UNO program, the series will shift to late January. Previous participation in other studies involving study intervention containing lipid nanoparticles. Phase 1 only: Positive test for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at the screening visit. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. Sammaurese were originally relegated on points per game: Crema 1.042, Sammaurese 1.040. Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. Série d'allocutions de l'ACSP sur les enjeux liés à la COVID-19 OTTAWA, ON, le 13 déc. [2], Rezzato, Francavilla and Gela opted not to register to the Serie D season.[6][2]. Phase 1 only: Individuals at high risk for severe COVID-19, including those with any of the following risk factors: To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. The reported death toll from the disease climbed by three on Thursday and by four on Friday, reaching a … Information provided by (Responsible Party): Participants ≥16 years of age who originally received placebo and are eligible for COVID-19 vaccination following any local or national recommendations will be offered the opportunity to receive BNT162b2 as part of the study. The 2019–20 Serie D was the seventy-second edition of the top level Italian non-professional football championship. The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part. regulation. Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: As a 2-dose (separated by 21 days) schedule; At various different dose levels in Phase 1; In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]). Capable of giving personal signed informed consent. Percentage of participants in Phase 1 reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ], Percentage of participants in Phase 1 reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ], Percentage of participants in Phase 1 reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ], Percentage of participants in Phase 1 reporting serious adverse events [ Time Frame: From dose 1 through 6 months after the last dose ], Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values [ Time Frame: 1 day after dose 1 ], Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values [ Time Frame: 7 days after dose 1 ], Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values [ Time Frame: 7 days after dose 2 ], Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between baseline and 1 day after dose 1 ], Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between baseline and 7 days after dose 1 ], Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between before dose 2 and 7 days after dose 2 ], In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ], In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ], In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ], In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events [ Time Frame: From dose 1 through 6 months after the last dose ], In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ], In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ], Percentage of participants in Phase 2/3 reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ], Percentage of participants in Phase 2/3 reporting serious adverse events [ Time Frame: From dose 1 through 6 months after the last dose ], Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Percentage of participants 12-15 years of age in Phase 3 reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ], Percentage of participants 12-15 years of age in Phase 3 reporting adverse events [ Time Frame: From dose 1 through 6 months after the last dose ], In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ], In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ], In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs [ Time Frame: Through 2 years after the final dose ], In Phase 1 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point [ Time Frame: Through 2 years after the final dose ], Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels [ Time Frame: Through 2 years after the final dose ], In Phase 1 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs [ Time Frame: Through 2 years after the final dose ], Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels [ Time Frame: Through 2 years after the final dose ], In Phase 1 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point [ Time Frame: Through 2 years after the final dose ], In Phase 1 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels [ Time Frame: Through 2 years after the final dose ], Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], GMR of SARS CoV 2 neutralizing titers in the 2 age groups (12-15 years of age to 16-25 years of age) [ Time Frame: 1 month after the second dose ].